IL2 and neoplasm: To harness the anti-tumor potential of IL-2 more effectively and expand its therapeutic window, the balance will have to shift towards the activation of anti-tumor immune cells while minimizing the expansion of immunosuppressive immune cell populations and their associated side effects by using novel strategies including fusion and pegylated proteins, as described below.